The new threats of Gram positive pathogens: Re-emergence of things past

Journal of Clinical Pathology

Volumn 49, Issue 6, 1996, Pages 444-449

  Howe, R A ^a   Brown, N M ^a   Spencer, R C ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; DIPHTHERIA; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; TREATMENT PLANNING;

EID: 0029920055     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.49.6.444     Document Type: Review

References (69)

1. Spencer RC. Invasive streptococci, Eur J Clin Microbiol Infect Dis 1995;14(Suppl 1):26 32.
2. Schwartz B, Fackham RR, Breiman RD. Changing epidemiology of group A streptococcal infections in the USA. Lancet 1990;336:1167-71.
3. Stroheck S, Jepsen OB, Zimakoff J, Ronne T. Increased number of sporadic nosocomial group A streptococcal bacteraemia during a community epidemic. J Hosp Infect 1991;19:129-36.
4. Steven DL. Invasive Group A streptococcal infections. Clin Infect Dis 1992;14:2-13.
5. Bisno AL. Group A streptococcal infections and acute rheumatic fever. N Engl J Med 1991;325:783-93.
6. Denny FW Jr, A 45-year perspective on the streptococcus and rheumatic fever: the Edward H Kass lecture in infectious disease history. Clin Infect Dis 1994;19:1110-22.
7. Gaworzewska E, Colman G. Changes in the pattern of infection caused by Streptococcus pyogenes. Epidemiol Infect 1988;100:257-69.
8. Cleary PP, Kaplan EL, Handley JP, Wlazlo A, Kim NH, Hauser AR, et al. Clonal basis for resurgence of serious Streptococcus pyogenes disease in the 1980's. Lancet 1992;339:518-21.
9. Hallas G. The production of pyrogenic exotoxins by Group A streptococci. J Hygiene 1985;95:47-57.
10. Talkington DF, Schwartz B, Black CM, Todd JK, Elliot J, Breiman RF, et al. Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome. Infect Immun 1993;61:3369-74.
11. Forni AL, Kaplan EL, Schlivert PM, Roberts RB. Clinical and microbiological characteristics of severe group A streptococcus infections and streptococcal toxic shock syndrome. Clin Infect Dis 1995;21:333-40.
12. Cone LA, Woodard DR, Schlievert PM, Tomory GS. Clinical and bacteriological observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med 1987;317:146-9.
13. Stevens DI, Gibbons AE, Bergstroum R, Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988;158:23-8.
14. Stevens DL, Yan S, Bryant AE. Penicillin-binding protein expression at different growth stages determines penicillin efficacy in-vitro and in-vivo: an explanation for the inoculum effect. J Infect Dis 1993;167:1401-5.
15. Gemmell CG, Peterson PK, Schmeling D, Kim Y, Mathews J, Wannamaker I, et al. Potentiation of opsonisation and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. J Clin Invest 1981; 67:1249-56.
16. Dale JB, Chiang EY, Lederer JW. Recombinant tetravalent group A streptococcal M protein vaccine. J Immunol 1993; 151:2188-94.
17. Shands KN, Schmid GP, Dan BB, Blum D, Guidotti RJ, Hargrett NT, et al. Toxic-shock syndrome in menstruating women: associated with tampon use and Staphylococcus aureus and clinical features in 52 cases. N Engl J Med 1980;303:1436-42.
18. Leung DYM, Meissner HC, Fulton DR, Murray DL, Kotzin BL, Schlievert PM, et al. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 1993;342:1385-8.
19. Meers PD, Ayliffe GAJ, Emmerson AM, Leigh DA, Mayon-White RT, Macintosh CA, et al. Report on the National Survey of Infections in Hospitals 1980. J Hosp Infect 1981; S2:1-11.
20. Spink WW, Ferris V. Quantitative action of penicillin inhibitor from penicillin-resistant strains of staphylococci. Science 1945;102:221.
21. Barber M. Methicillin-resistant staphylococci. J Clin Pathol 1961;14:385.
22. Bell SM. Recommendations for the control of the spread of methicillin-resistant Staphylococcus aureus infection. Based on 18 years' experience in a group of teaching hospitals. Med J Aust 1982;1:472-4.
23. Kerr S, Kerr GE, Mackintosh CA, Marples RR. A survey of methicillin-resistant Staphylococcus aureus affecting patients in England and Wales. J Hosp Infect 1990;16:35-48.
24. Duckworth G. Revised guidelines for the control of epidemic methicillin-resistant Staphylococcus aureus. J Hosp Infect 1990;16:351 77.
25. Epidemic methicillin resistant Staphylococcus aureus. Communicable Discase Report 1995;5:165.
26. Schwalbe RS, Stapleton JT, Gillingan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 1987;316:927-31.
27. Kaatz GW, Seo SM, Dorman NJ, Lerner SA. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. J Infect Dis 1990;162:103-8.
28. Noble WC, Virani Z, Gee GA. Co-transfer of vancomycin and resistant genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Len 1992;93:195-8.
29. Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin United States, 1989-1993. MMWR 1993;42;597 9.
30. Moellering RC. The enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic options. J Antimicrob Chemother 1991;28:1 12.
31. Williamson R, LeBouguénec C, Gutmann L, Horaud T. One or two low affinity penicillin-binding proteins may be responsible for the range of susceptibility of Enterococcus faecium to benzylpenicillin. J Gen Microbiol 1985; 131:1933-40.
32. Uttley AHC, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1988;i:57-8.
33. Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988;319:157 61.
34. Arthur M, Courvalin P. Genetics mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother 1993;37:1563 71.
35. Shay DK, Maloney SA, Montecalvo M, Banerjee S, Wormser GP, Ardiuno MJ, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995;172:993-1000.
36. Jordens JZ, Bates J, Griffiths DT. Faecal carriage and nosocomial spread of vancomycin-resistant Enterococcus faecalis. J Antimicrob Chemother 1994;34:515-28.
37. Freiden TR, Munsiff SS, Low DE, Willey BM, Williams G, Faur Y, et al. Emergence of vancomycin-resistant enterococci in New York City. Lancet 1993;342:76-9.
38. Korten V, Murray BE. The nosocomial transmission of enterococci. Curr Opin Infect Dis 1993;6:498-505.
39. Murray BE, Editorial response: What can we do about vancomycin-resistant enterococci? Clin Infect Dis 1995; 20:1134-6.
40. Recommendations for preventing the spread of vancomycin-resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HIC-PAC). MMWR 1995;44:1 13.
41. McFarlane J. The clinical impact of pneumococcal disease. In: Mayon-White RT, ed. The clinical impact of pneumococcal disease and stratogies fur its prevention. International congress and Symposium Series No 210. London: Royal Society of Medicine Press Ltd, 1995:9-17.
42. Aszkenasy OM, George RC, Begg NT. Pneumococcal bacteraemia and meningitis in England and Wales 1982 to 1992. Communicable Disease Report 1995;5:R45 50.
43. Lister PD. Multiply-resistant pneumococcus: therapeutic problems in the management of serious infections. Eur J Clin Microbiol Infect Dis 1995;14(Suppl 1):18-25.
44. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: An overview. Clin Infect Dis 1995;15:77 83.
45. Hofman J, Cetron MS, Farley MM, Baughman WS, Facklam RR, Elliott JA, et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995;333:481 6.
46. Geslin P, Buu-Hoi A, Fremaux A, Acar JF. Antimicrobial resistance in Streptococcus pneumoniae: An epidemiological survey in France, 1970-1990. Clin Infect Dis 1992; 15:95-8.
47. Lee HJ, Park JY, Jang SH, Kim JH, Kim EC, Choi KW, et al. High incidence of resistance to multiple antimicrobials in clinical isolates of Streptococcus pneumoniae from a university hospital in Korea. Clin Infect Dis 1995;20:826-35.
48. Antimicrobial resistance of pneumococi isolated from blood and cerebrospinal fluid 1993 and 1994. Communicable Disease Report 1995;5:187-8.
49. Coffey TJ, Dowson CG, Daniels M, Spratt B. Genetics and molecular biology of β-lactam-resistant pneumococci. Microbial Drug Resistance 1995;1:29-34.
50. McDougal LK, Facklam R, Reeves M, Hunter S, Swenson JM, Hill BC, et al. Analysis of multiple antimicrobial-resistant isolates of Streptococcus pneumoniae from the United States. Antimicrob Aegnts Chemother 1992;36:2176 84.
51. Caputo GM, Appelbaum PC, Liu HH. Infections due to penicillin-resistant pneumococci. Arch Intern Med 1993; 153:1301-10.
52. Pallares R, Linares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995;333:474 80.
53. Friedland IR, McCracken GH. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994;331:377 82.
54. John CC. Treatment failure with use of a third-generation cephalosporin for penicillin-resistant pneumococcal meningitis: case report and review. Clin Infect Dis 1994;18:188-93.
55. Johnson AP, Speller DCE, Patel BC. Sensitivity to cefotaxime of pneumococci isolated in the UK. J Antimicrob Chemother 1995;35:443-4.
56. Taylor I, Tomlinson AJH, Davies JR. Diphtheria control in the 1960's. J R Soc Health 1962;82:158-64.
57. White JM, Leon S. 'COVER' (Cover of vaccination evaluated rapidly): 34. Communicable Disease Report 1995; 5:R105-6.
58. A case of diphtheria from Pakistan. Communicable Disease Report 1994;4:173.
59. Maurice J. Belated attempts to contain Russia's diphtheria. Lancet 1995;345:715.
60. Maple PA, Efstratiou A, George RC, Andrews NJ, Sesardic D. Diphtheria immunity in UK blood donors. Lancet 1995;345:963-5.
61. Miller E, Rush M, Morgan-Capner P, Hutchinson D, Hindle L. Immunity to diphtheria in adults in England. BMJ 1994;308:598.
62. Begg N. WHO Manual for the management and control of diphtheria in the European Region. 1994;ICP/EPI 038.
63. Department of Health. Diphtheria immunisation and treatment. CMO's Update 1995;5:1.
64. Efstratiou A, George RC, Begg NT. Non-toxigenic Corynebacterium diphtheriae var gravis in England. Lancet 1993; 341:1592-3.
65. Wilson APR. The return of Corynebacterium diphtheriae: the rise of non-toxigenic strains. J Hosp Infect 1995; 30(Suppl A):306-12.
66. Gruner E, Opravil M, Altvegg M, von Graevenitz A. Nontoxigenic Corynebacterium diphtheriae isolated from intravenous drug users. Clin Infect Dis 1994;18:94-6.
67. Zuber PTF, Gruner E, Altwegg M, von Graevenitz A. Invasive infection with non-toxigenic Corynebacterium diphtheriae among drug users. Lancet 1992;339:1359.
68. Tiley SM, Kociuba KR, Heron LG, Munro R. Infective endocarditis due to non-toxigenic Corynebacterium diphtheriae: Report of seven cases and review. Clin Infect Dis 1993;16:271-5.
69. Freeman VJ. Studies on the virulence of bacteriophage-infected strains of Corynebacterium diphtheriae. J Bacteriol 1951;61:675-88.